The authors specifically note The shortage of randomized managed trials for orthopaedic indications—meaning we could’t confidently say it works, what the actual facet-impact profile is, or what a “safe dose” would be in the real earth (systematic evaluation, 2024).Should the aim is “less downtime, a lot more teaching,” there’s a lot y